N-PHOSPHONYLMETHOXYALKYL DERIVATIVES OF PYRIMIDINE AND PURINE BASES, METHODS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREFROM WITH ANTIVIRAL ACTIVITY

Abstract: This invention relates to new nucleotide analogues exhibiting antiviral activity which represent N-(2-­ phosphonylmethoxyethyl) and N-(3-hydroxy-2-phosphonyl­ methoxypropyl) derivatives of pyrimidine and purine bases and to methods for their preparation and to their use in pharmaceutical compositions. These compounds are easily accessible from heterocyclic bases and their N-(2-hydroxy­ ethyl) or N-(2,3-dihydroxypropyl) derivatives. Some of the compounds according to this invention exhibit a marked antiviral activity or can be converted into such active compounds by chemical transformations.

Description: This invention relates to N-phosphonylmethoxyalkyl derivatives of pyrimidine and purine bases, methods for their preparation and to the use of these compounds in pharmaceutical compositions with antiviral activity. Some substituted N-alkyl derivatives of heterocyclic bases exhibit important biological effects. Among them are e.g. theophylline derivatives such as Diprophyllin® and Proxyphyllin® (bronchodilatory effect), guanine derivatives with antiviral activity, such as Zovirax®, 9-(1,3-dihydroxy-2-propoxymethyl)-guanine, (DHPG, nor-2'-­ deoxyguanosine, BIOLF-62) and 9-(4-hydroxybutyl)-guanine (HGB), adenine derivatives such as 9-(S)-(2,3-dihydroxy-­ propyl)-adenine (DHPA), 3-(adenin-9-yl)-2-hydroxypropanoic acid (AHPA) and its esters, all having antiviral activity (for a review see e.g. M.J. Harnden, ed., Approaches to Antiviral Agents; Macmillan, London 1985, pp. 101-134). Significant biological effects have been found also for erythro-9-(2-hydroxynonyl)-adenine (EHNA), 1-(2-hydroxy-­ ethoxymethyl)-5-benzyluracil and 1-(1,3-dihydroxy-2-­ propoxymethyl)-5-benzyluracil which are specific inhibitors of catabolic enzymes with possible application in combination chemotherapy of metabolic or malignant diseases. Most of these compounds can be regarded as so-called acyclic analogues of nucleosides in which the nucleoside sugar moiety is replaced by a substituted carbon chain bearing hydroxy groups. In the organism, the biologically active nucleoside analogues with chemically modified heterocyclic bases or sugar moieties are usually phosphorylated to give 5'-monophosphates which then act as so-called active antimetabolites. However, attempted therapeutical applications of such compounds were not particularly successful: although in some cases the physical and pharmacological parameters (solubility, higher absorption, prolonged activity etc.) have been improved as compared with those of the corresponding nucleoside analogues, the main obstacle to the thera­ peutical use of the phosphoric acid esters remains their facile dephosphorylation in the organism. This dis­ advantage can be overcome by a suitable chemical modification of the phosphoric acid-nucleoside bond. However, compounds of this type described so far have not been therapeutically useful. On the other hand, it is known that 9-(ω-phosphonylalkyl)-­ hypoxanthines inhibit purine nucleoside phosphorylase - an important target enzyme in the therapy of metabolic and malignant diseases (C.E. Nakamura, S.H. Chu, J.D. Stoeckler and R.E. Parks Jr., Biochem. Pharmacol. 35 (1986) 133-136). Also an antiviral effect of 9-(phosphonylalkoxymethyl)-purines has been reported (U.S. Patent Appl. 497720 (1983)). This group of compounds which is characterized by a modified phosphoric acid residue comprises also two extraordinarily important acyclic nucleotide analogues: 9-(S)-(2-phosphonylmethoxy-3-­ hydroxypropyl)-adenine (HPMPA) (CS Author's Certificate 233665) and 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) (CS-patent application-3017-85). Both these compounds are very potent antivirals, acting specifically against DNA viruses (CS-patent application-3018-85). Viruses of this group, e.g. herpes viruses (herpes simplex, herpes zoster, cytomegalo viruses, Epstein-Barr virus), pox viruses and adenoviruses, can inflict serious diseases. Some of these diseases have so far been treated with the above-mentioned antivirals (Zovirax®, DHPG; D.S. Freestone, Antiviral Res. 15 (1985) 307-324). The application of these drugs is limited not only by their low water-solubility and side-­ effects but mainly by the dependence of their activity on the presence of a specific viral enzyme, thymidine kinase. Those strains or mutants of the above viruses that are devoid of this enzyme are not sensitive to the antivirals mentioned. These strains are usually also resistant toward modified nucleoside antivirals, e.g. 5-(2-bromovinyl)-2′-­ deoxyuridine. The acyclic nucleotide analogues HPMPA and PMEA are active even in cases where the above-mentioned drugs fail. This invention is based on the new and unexpected finding that the antiviral effect of acyclic nucleotide analogues is not limited to the adenine derivatives HPMPA and PMEA only. It is the object of the present invention to provide new N-phosphonylmethoxyalkyl derivatives having antiviral activity, methods for their preparation and their use in pharmaceutical compositions for the treatment of virus diseases. The above object is achieved according to claims 1 and 7 to 11. The dependent claims are related to preferred embodi­ ments. The new N-phosphonylmethoxyalkyl derivatives according to the invention are derivatives of pyrimidine and purine bases and have the general formula I, B-CH₂-H-OCH₂P(O)(OH)₂ (I), wherein R is a hydrogen atom or a hydroxymethyl group and B is an optionally substituted pyrimidin-1-yl, pyrimidin-­ 3-yl, purin-3-yl, purin-7-yl or purin-9-yl residue, whereby unsubstituted adenin-9-yl is excluded; the invention relates also to the salts thereof with alkali metals, ammonia and amines. The substituent B can be substituted e.g. with methyl, amino, bromo, fluoro, hydroxy and/or thio groups. In formula I, the substituent B is preferably Uracil-1-yl, Thymin-1-yl, Cytosin-1-yl, 6-Methylpurin-9-yl, Guanin-9-yl, Hypoxanthin-9-yl, Adenin-9-yl, 2-Aminoadenin-9-yl, 8-Bromoadenin-9-yl, 2-Aminopurin-9-yl, 6-Hydrazinopurin-9-yl, 7-Deaza-8-azaadenin-9-yl, 7-Deaza-8-azahypoxanthin-9-yl, 5-Methylcytosin-1-yl, 5-Fluorouracil-1-yl, Guanin-7-yl, Adenin-3-yl, Hypoxanthin-9-yl, 2-Methyladenin-9-yl, 2-Methylthioadenin-9-yl, N⁶-Dimethyladenin-9-yl, 8-Hydroxyadenin-9-yl, 6-Hydroxylaminopurin-9-yl, 6-Thiopurin-9-yl, Purin-9-yl, or Xanthin-9-yl. This invention further relates to pharmaceutical compositions exhibiting antiviral activity, containing one or more compounds of the general formula I as active ingredients in a concentration of 0,01 to 100 mass-%. The antiviral effect of compounds of the general formula I can be utilized for the therapy of viral diseases, e.g. diseases caused by DNA viruses. An important property of the compounds of the general formula I is their antiviral effect against those DNA viruses which are resistant to the hitherto known antivirals, e.g. against TK⁻mutants of herpes viruses. Contrary to the hitherto known antiviral nucleoside analogues, derived usually from a single heterocyclic base (Zovirax, DHPG and HBG are guanine derivatives, whereas DHPA, AHPA and Vidarabin are derived from adenine), the antiviral effect of compounds of the general formula I is not limited to a specific hetero-­ cyclic base. This fact indicates a completely different mechanism of action of the compounds of the general formula I which is supported also by their activity against strains and mutants resistant to other antivirals. In addition to the already mentioned adenine derivatives (HPMPA, PMEA), also the chemically substantially different cytosine and guanine derivatives of the formula I are highly effective against TK⁻ mutants of herpes viruses type 1 and 2 as well as against vaccinia virus. Moreover, the cytosine compounds of the general formula I may be more easily accessible than the adenine derivatives (HPMPA, PMEA). The pharmaceutical compositions according to this invention containing as active ingredient compounds of general formula I can be applied in the form of powders, suspensions, solutions, sprays, emulsions, pastes, ointments, etc. and can be used for parenteral administrations (intravenous, intradermal, intramuscular, intrathecal, etc.) as well as for oral, rectal, intra­ vaginal or intranasal administration or topical applications. Such compositions can be prepared by mixing or dissolving the salt or the free acid of the compounds of the general formula I with usual pharmaceutically acceptable carriers, stabilizers, solvents, wetting agents and/or additives etc. According to the requirements and application form these preparations can contain various concentrations of the compounds of the formula I, from 0,01 up to 100 wt-%. Compounds of the general formula I, wherein R is a hydrogen atom (i.e. 2-phosphonylmethoxyethyl derivatives of heterocyclic bases) can be prepared in analogy to the procedure elaborated for PMEA (CS-PV-3017-85), i.e. by reaction of N-(2-hydroxyethyl) derivatives of the corresponding heterocyclic bases having the general formula II B-CH₂CH₂OH (II), wherein B has the same signification as in formula I, with diesters of p-toluenesulfonyloxymethanephosphonic acid and subsequent reaction with trimethylhalogeno-­ silanes, or by reaction of an alkali metal salt of the heterocyclic bases with diesters of 2-bromoethoxymethane­ phosphonic acid of the general formula III BrCH₂CH₂OCH₂P(O) (OC₂H₅)₂ (III) to give intermediates of the general formula IV B-CH₂CH₂OCH₂P(O) (OC₂H₅)₂ (IV), wherein B is the same as in formula I, followed by treatment with trimethylhalogenosilanes. The compounds of the general formula I, wherein R is a hydroxymethyl group, i.e. the N-(3-hydroxy-2-phosphonyl­ methoxypropyl) derivatives of heterocyclic bases, contain one asymmetric carbon atom. Both the enantiomeric forms as well as the racemates can be prepared from the N-(2,3-­ dihydroxypropyl) derivatives of heterocyclic bases of the general formula V B-CH₂CH(OH)CH₂OH (V), accessible from the corresponding heterocyclic bases by a number of synthetic procedures (A. Holy, Collect. Czechos­ lov. Chem. Commun. 40 (1975) 187; ibid 43 (1978) 3103). They can be converted into compounds of the formula I by reaction of specifically protected derivatives of compounds of the formula V, containing a free 2-hydroxy group, with the above-mentioned diesters of p-toluene-­ sulfonyloxymethanephosphonic acid and subsequent cleavage with trimethylhalogenosilanes (CS-A-3017-85). A more ad­ vantageous procedure, however, consists in the reaction of unprotected compounds of the formula V with chloromethane­ phosphonyl dichloride of the formula VI ClCH₂P(O)Cl₂ (VI) either in pyridine (CS-Author's Certificate 233665) or advantageously in triethyl phosphate, and subsequent iso­ merization of the formed 2′-O-chloromethanephosphonyl esters of the compounds V to the corresponding 3′-O-­ chloromethanephosphonyl esters of the general formula VII B-CH₂-CH₂OP(O)(OH)CH₂Cl (VII), wherein B has the same signification as in formula I, in a mineral acid or water. Treatment of compounds of the formula VII with aqueous alkali metal hydroxides (according to CS Author's Certificate 233665) affords compounds of the formula I (wherein R is hydroxymethyl) in practically quantitative yields. Further compounds of the general formula I can be prepared by chemical transformations of the heterocyclic base; accordingly, e.g. the reaction of uracil derivatives (I, B being uracil-1-yl with bromine or iodine affords compounds of the formula I, wherein B is 5-halogenouracil-­ 1-yl, treatment of adenine derivatives (HPMPA, PMEA) with nitrous acid or amyl nitrite leads to compounds of the formula I, wherein B is a hypoxanthin-9-yl moiety, and a similar deamination of guanine derivatives gives compounds I wherein B is a xanthin-9-yl moiety. Also substitution at the purine base, e.g. with chlorine, in the pre-formed skeleton of compounds of the general formula I leads to the corresponding N-phosphonylmethoxyalkyl-8-halogenopurines. On the other hand, compounds of the general formula I, wherein B is a 2-methylthioadenin-9-yl, can be transformed into HPMPA or PMEA by desulfuration reaction, e.g. with Raney nickel. The transformation of the heterocyclic ring can be utilized particularly in such cases where the reaction conditions in the preparation of compounds of the formula I from the heterocyclic base do not afford the desired isomer (hypoxanthine, xanthine) or lead to destruction of the heterocyclic base (mainly due to the use of strong alkali in the reaction of the intermediate of formula VII). Halogene derivatives of the pyrimidine or purine series can also serve as starting compounds for further transformations of the heterocyclic base. The heterocyclic base in compounds of the general formula I may be not only a so-called natural pyrimidine or purine base (uracil, thymine, cytosine, guanine, adenine, hypo­ xanthine, xanthine) or substituted derivatives thereof, but also a modified base such as an aza, deaza, deoxy or deamino analogue, a 6-alkylpurine, etc. The N-phosphonylmethoxyalkyl derivatives of the general formula I are acids of medium strength. They can be easily purified by chromatography on anion exchange resins (such as Dowex 1, Sephadex A-25, DEAE cellulose etc.), preferably involatile organic acids, (e.g. acetic acid or formic acid) or in volatile neutral buffers (e.g. tri­ ethylammonium hydrogen carbonate). Some of the compounds according to the invention (particularly those with basic heterocyclic moieties) can be stored as free acids which, however, may be sparingly soluble in water. Higher solubility is achieved by conversion of the free acids into well-soluble salts, particularly alkali metal salts (sodium, lithium), by neutralization or (from the acids or other salts) by ion-exchange. The compounds of the general formula I can be easily characterized by their ultraviolet spectra, paper chromatography, high performance liquid chromatography or paper electrophoresis; at the same time, these methods serve to prove homogeneity. The antiviral activity of the compounds of the general formula I is determined by measurement of their inhibitory effect on virus-induced cytopathogenicity, e.g. on PRK-­ cells (primary rabbit kidney cells) in tissue cultures previously infected with the corresponding virus and then cultivated ina medium containing various concentrations of the compounds of the general formula I. The compound is regarded as significantly active if an effect is observed at a concentration not exceeding 100 µg·ml⁻¹ of medium without changing markedly the cell morphology in the control (virus-uninfected) culture of the same cells under the same conditions. A survey of the effect of compounds of the formula I on some representative viruses is given in table 1; the preparation of the compounds is described in the examples, and their characteristics are given in table 2. Example 1 Determination of antiviral activity of compounds of the general formula I in cell cultures Confluent monolayers of primary rabbit kidney cell cultures (PRK-cells) in microtiter tray wells in Eagle minimum essential medium (EMEM) are inoculated with the virus (100 CCID₅₀; 1 CCID₅₀ representing the amount of the virus required for infecting 50 % of the cells under the given conditions) for 1 hour. Then the virus solution is removed, the culture is washed with the basic medium and cultivated in solutions of EMEM containing various concentrations (M/V) of compounds of the formula I. The cytopathogenic effect of the virus in these cultures is evaluated at the time of achieving 100 % in the control, infected culture, cultivated in the medium alone. The antiviral effect is expressed as MIC₅₀ (µg·ml⁻¹) (minimum concentration of compound of the formula I which reduces the cytopathogenic effect of the virus to 50 %) and is obtained from a series of measurements at various concentrations of compounds I. The antiviral activities of compouds of the general formula I are given in table 1 in comparison with prior art antivirals. Example 2 Preparation of compounds of the general formula I (R = H) A solution of diethyl 2-bromoethoxymethanephosphonate (2,75 g; 10 mmol) in dimethylformamide (10 ml) is added dropwise at 80 °C during 2 - 3 hours under exclusion of moisture to a stirred solution of sodium salt of the heterocyclic base, (prepared from 10 mmol of the base and 0,24 g (10 mmol) of sodium hydride in 80 ml of dimethyl­ formamide). After stirring at 80 °C for 3 - 5 hours, the solvent is evaporated at 13 Pa and the residue is extracted with boiling chloroform (400 - 500 ml). The extract is concentrated in vacuo and chromatographed on a column of silica gel (200 ml) in ethanol - chloroform (gradient elution), affording chromatographically homo­ geneous compound IV which can be crystallized from a mixture of ethyl acetate (or ethanol) and light petroleum. This product is treated with trimethylbromosilane (2,4 ml) in acetonitrile (40 ml) for 16 hours at room temperature. The solvent is then evaporated at 2 kPa, the residue is dissolved in 10 % triethylamine solution in 50 % (V/V) aqueous acetonitrile and after 30 min the solvent is again evaporated at 2 kPa. The residue is chromatographed on a column of Sephadex A-25 (HCO⁻₃; 150 ml) with a linear gradient (2 litres total) of 0,02 - 0,2 mol·1⁻¹ triethyl­ ammonium hydrogen carbonate, pH 7,5. The main UV-absorbing fraction containing the compound I is concentrated by evaporation, and the buffer is removed by repeated co-­ destillation with methanol (all the evaporations are done at 2 kPa), the residue is dissolved in water (20 ml) and applied onto a column of Dowex 50 x 8 (Na⁺-form; 50 ml) and eluted with water. The UV-absorbing eluate is concentrated by evaporation, and the product is precipitated from methanol with ether. The sodium salt of compound I (R = H ) thus-obtained is isolated in a yield of 80 - 90 % (based on compound V). Compounds of the general formula I prepared in this manner are listed in table 2. Example 3 Preparation of compounds of the general formula I (R = H) The reaction is carried out with 10 mmol of the hetero­ cyclic base as described in example 2. The dimethyl­ formamide is evaporated at 13 Pa and instead of extraction with chloroform, the intermediate IV is heated 8 hours with 1 mol·1⁻¹ sodium hydroxide (50 ml) at 80 °C. After neutralization with a cation exchange resin (H⁺-form), the mixture is made alkaline with triethylamine, filtered, concentrated by evaporation at 2 kPa, and the residue is dried at 13 Pa over phosphorus pentoxide. The reaction with trimethylbromosilane and the work-up procedure are carried out as described in example 2. Compounds of the general formula I, prepared in this way, are also listed in table 2. Example 4 Preparation of compounds of the general formula I (R = CH₂OH) Chloromethanephosphonyl dichloride (0,40 ml) is added to a stirred mixture of the N-(2,3-dihydroxypropyl) derivative V and triethyl phosphate (10 ml). After stirring for 16 hours in a stoppered flask, ether (80 ml) is added, and the formed precipitate is filtered, washed with ether and dried at 13 Pa. A solution of this material in water (20 ml) is refluxed for 8 hours, neutralized with tri­ ethylamine, and the solvent is evaporated at 2 kPa. The residue is dissoved in water (1,5 ml); 0,3 ml portions of this solution are applied onto a column (8 x 500 mm) of octadecyl-silica gel (e.g. Separon SIX C18, 7 µm), equilibrated with 0,05 mol·1⁻¹ triethylammonium hydrogen carbonate, pH 7,5. The column is washed with the same buffer until the salts are removed and then with a step-­ wise gradient of methanol in the same buffer (usually to 10 vol-%), elution rate 2 ml·min⁻¹. From the combined eluates, containing compound VII, the solvent is stripped at 2 kPa, and the product is heated with 2 mol·1⁻¹ sodium hydroxide (10 ml) to 80 °C. the mixture is neutralized with a cation-exchanger (H⁺-form) and filtered, and the solvent is removed at 2 kPa. The further processing is the same as described in example 2 and affords the sodium salt of compound I (R = CH₂OH) in a yield of 50-60 % (based on compound V). Compounds of the formula I prepared in this manner are listed in table 2. Example 5 Preparation of compounds of the general formula I (R = CH₂OH) The reaction is carried out as described in example 4. After boiling the reaction intermediate in the aqueous solution, the content of compound VII is determined by HPLC (usually more than 80 % of the isomer mixture). The mixture is neutralized with sodium hydroxide, concentrated by evaporation at 2 kPa and the residue is heated to 80 °C with 2mol·1⁻¹ sodium hydroxide (20 ml) for 10 hours. The solution is then neutralized with a cation-exchange resin (H⁺-form), made alkaline with triethylamine, filtered and evaporated at 2 kPa. The crude product is purified by chromatography on Sephadex A-25 as described in example 2, affording the sodium salt of compound I (R = CH₂OH) which contains more than 80 % of this isomer. Example 6 To a solution of sodium salt of 9-(2-phosphonylmethoxy­ ethyl)-adenine (4 mmol) in 80 % acetic acid (50 ml) is added to 3-methylbutyl nitrite (4 ml). After standing in a stoppered flask for 72 hours at room temperature, the solvent is evaporated at 2 kPa and the residue repeatedly co-distilled with water to remove traces of acetic acid. The residue is dissolved in water (10 ml), applied onto a column (200 ml) of a cation-exchange resin (e.g. Dowex 50 x 8 ) (H⁺-form) and eluted with water to drop UV absorption. This eluate is evaporated at 2 kPa; the residue is co-distilled with ethanol, crystallized from ethanolether (10 ml : 50 ml), filtered, washed with ether and dried at 13 Pa. Yield 0,93 g (90 %) of 9-(2-­ phosphonylmethoxyethyl)-hypoxanthine (free acid), not melting up to 260 °C. Example 7 Bromine (0,5 ml) is added to a stirred solution of sodium salt of 9-(S)-(3-hydroxy-2-phophonylmethoxypropyl)-­ adenine (2 mmol) in 1 mol·1⁻¹ sodium acetate, pH 4,0 (40 ml). After stirring at room temperature for 2 days, the mixture is decolorized with a saturated solution of sodium hydrogen sulfite, and the whole solution is applied onto a column of a cation-exchange resin (e.g. Dowex 50 x 8) (H⁺-form; 150 ml). After washing the column with water to drop conductivity and UV absorption, the product is eluted with 2 % (V) aqueous ammonia. The ammonia cell UV-absorbing eluate is evaporated at 2 kPa, and the residue in water is filtered through a column of octadecyl-silica gel (80 ml). The UV-absorbing eluate is again evaporated at 2 kPa, dissolved in water (5 ml) and applied onto a column of Dowex 50 x 8 (Na⁺-form; 50 ml). The column is washed with water, the UV-absorbing eluate is concentrated by evaporation at 2 kPa, and the residue is co-distilled with ethanol, mixed with ethanol (10 ml) and ether (100 ml) and collected on a filter. Yield 55 % of sodium salt of 9-(S)-(3-hydroxy-2-phosphonylmethoxy­ propyl)-8-bromoadenine which (according to HPLC analysis) contains less than o,5 % of the starting compound. Example 8 Sodium salt of 9-(RS)-(3-hydroxy-2-phosphonylmethoxy­ propyl)-2-methylthioadenine (2,0 g) is added to moist Raney nickel (7 g) in 0,2 mol 1⁻¹ sodium hydroxide (25 ml). After stirring under reflux for 72 hours, the hot mixture is filtered through Celite which is then washed with boiling water (100 ml), and the filtrate is neutralized with a cation-exchanger (H⁺-form). According to HPLC analysis, the product contains 75-80 % of the reaction product. After evaporation, the residue is dissolved in water (10 ml) and applied onto a column of octadecyl-silica gel (20 µm, 180 ml) in 0,05 mol 1⁻¹ tri­ ethylammonium hydrogen carbonate, pH 7,5. The product is eluted with the same buffer, elution rate 1 ml min⁻¹, fractions of 20 ml, monitored by HPLC (see table 2). The product-containing fractions are combined and evaporated at 2 kPa, and the product is converted into the sodium salt of (RS)-HPMPA as described in example 2; yield 65-70 %.

Claims: 1. N-Phosphonylmethoxyalkyl derivatives of pyrimidine and purine bases of the general formula I, B-CH₂H-OCH-₂P(O)(OH)₂ (I), wherein R is a hydrogen atom or a hydroxymethyl group and B is an optionally substituted pyrimidin­ 1-yl, pyrimidin-3-yl, purin-3-yl, purin-­ 7-yl or purin-9-yl residue, whereby unsubstituted adenin-9-yl is excluded, and the salts thereof with alkali metals, ammonia and amines. 2. N-Phosphonylmethoxyalkyl derivatives of formula I according to claim 1, wherein the residues B are aza, deaza, deoxy or deamino analogues of uracil, thymine, cytosine, guanine, adenine, hypoxanthine or xanthine. 3. N-Phosphonylmethoxyalkyl derivatives of formula I according to claim 1, wherein the residue B is 6-alkylpurin-3-yl, 6-alkylpurin-7-yl or 6-alkyl-9-yl or a derivative thereof. 4. N-Phosphonylmethoxyalkyl derivatives of formula I according to one of claims 1 to 3, wherein the substituent B is substituted with a methyl, amino, bromo, fluoro, hydroxy and/or a thio group. 5. N-Phosphonylmethoxyalkyl derivatives of formula I according to claim 1, wherein B is Uracil-1-yl, Thymin-1-yl, Cytosin-1-yl, 6-Methylpurin-9-yl, Guanin-9-yl, Hypoxanthin-9-yl, Adenin-9-yl, 2-Aminoadenin-9-yl, 8-Bromoadenin-9-yl, 2-Aminopurin-9-yl, 6-Hydrazinopurin-9-yl, 7-Deaza-8-azaadenin-9-yl, 7-Deaza-8-azahypoxanthin-9-yl, 5-Methylcytosin-1-yl, 5-Fluorouracil-1-yl, Guanin-7-yl, Adenin-3-yl, Hypoxanthin-9-yl, 2-Methyladenin-9-yl, 2-Methylthioadenin-9-yl, N⁶-Dimethyladenin-9-yl, 8-Hydroxyadenin-9-yl, 6-Hydroxylaminopurin-9-yl, 6-Thiopurin-9-yl, Purin-9-yl, or Xanthin-9-yl. 6. N-Phosphonylmethoxyalkyl derivatives of formula I according to one of claims 1 to 5 representing the following combination of R and B and having the indicated C²-configuration: 7. Methods for preparing the N-phosphonylmethoxyalkyl derivatives of formula I according to one of claims 1 to 6, wherein R is hydrogen atom, characterized by (A) - reaction of N-(2-hydroxyethyl) derivatives of the corresponding heterocyclic bases having the formula II B-CH₂CH₂ (II), wherein B is as in formula I of claim 1, with diesters of p-toluenesulfonyloxymethane­ phosphonic acid, and -cleavage with a trimethylhalogenosilane, or (B) - reaction of an alkali metal salt of the hetero­ cyclic bases with diesters of 2-bromoethoxy­ methanephosphonic acid of the general formula III Br-CH₂CH₂OCH₂P(O)(OC₂H₅)₂ (III) to give intermediates of the general formula IV B-CH₂CH₂OCH₂P(O)(OC₂H₅)₂ (IV), and - treatment with a trimethylhalogenosilane. 8. Methods for preparing the N-phosphonylmethoxyalkyl derivatives of formula I according to one of claims 1 to 6, wherein R is a hydroxymethyl group, characterized by (A) - reaction of a protected N-(2,3-dihydroxypropyl) derivative of the heterocyclic bases of the general formula V, B-CH₂CH(OH)CH₂-OH (V), wherein B is as in formula I of claim 1, and having a free 2-hydroxy group with diesters of p-toluenesulfonyloxymethane­ phosphonic acid and - cleavage with a trimethylhalogenosilane, or (B) - reaction of unprotected compounds of formula V with chloromethanephosphonyl dichloride of the formula VI Cl-CH₂P(O)Cl₂ (VI), - isomerization of the formed 2′-O-chloromethane­ phosphonyl esters of the compounds of formula V in a mineral acid or in water to the corresponding 3′-O-chloromethanephosphonyl esters of the general formula VII B-CH₂-CH₂OP(O)(OH)CH₂-Cl (VII), and - treatment of the compounds of formula VII with an aqueous alkali metal hydroxide. 9. Methods for preparing N-phosphonylmethoxyalkyl derivatives of formula I according to one of claims 1 to 6, characterized in that - for preparing compounds of formula I wherein B is 5-halogenouracil-1-yl, an uracil-1-yl derivative of formula I is halogenated, preferably with bromine or iodine; - for preparing compounds of formula I wherein B is a hypoxanthin-9-yl moiety, a corresponding adenine derivative, particularly HPMPA or PMEA, is deaminated with nitrous acid or amyl nitrite; - for preparing compounds of formula I wherein B is a xanthin-9-yl moiety, a corresponding guanine derivative is deaminated with nitrous acid or amyl nitrite, and - for preparing compounds of formula I wherein B is an 8-halogenopurine, the corresponding purine base is halogenated, preferably with chlorine. 10. Pharmaceutical compositions exhibiting antiviral activity, characterized in that they comprise at least one N-phosphonylmethoxyalkyl derivative of formula I as active ingredient in a concentration of from 0,01 to 100 mass-%. 11. Use of the N-phosphonylmethoxyalkyl derivatives of formula I according to one of claims 1 to 6 for preparing pharmaceutical compositions for the treatment of virus diseases.

Inventors: DE CLERCQ, ERIK, PROF.DR., HOLY, ANTONIN, RNDR, ROSENBERG, IVAN
Applicants: CESKOSLOVENSKA AKADEMIE VED, REGA FOUNDATION
Application year: 1987
Main classification: C07F9
IPC codes: A61K31, A61P31, C07F9